Astellas Pharma, Inc.

1,817.00 JPY
+8.50
+0.47%

Japan
Jul 20, 2018
Ticker
TKS(4503)
Prev. close
1,808.5
Market cap (JPY)
3,580.51B
Market cap (USD)
32,016M
Shares
1,979.82M

In the news

China extends drug patents to 25 years May 16, 2018
Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
Goldman and Nomura lead all-star team behind Takeda-Shire deal May 10, 2018
Japan's Astellas sees cancer drug fueling 29% profit growth Apr 27, 2018
Takeda chases global status with $64bn shortcut Apr 26, 2018

See more articles on Astellas Pharma, Inc.

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018	JPY	USD
Revenue	1,300.31B	11,732.27M
Gross Profit	970,228M	8,754.00M
Operating income	271,241M	2,447.30M
Income before tax	218,113M	1,967.95M
Net income	164,679M	1,485.83M
EBITDA	336,104M	3,032.54M
Diluted EPS	81.02	0.73
Dividends Per Share	36	0.32
Total Assets	1,858.20B	17,472.54M
Total liabilities	583,608M	5,487.61M
Total equity	1,268.28B	11,925.61M
Operating cash flow	314,463M	2,837.28M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018
Revenue	1,139.90B	1,247.25B	1,372.70B	1,311.66B	1,300.31B
Gross Profit	773,281M	875,398M	994,723M	955,325M	970,228M
Operating income	184,803M	216,283M	269,638M	276,419M	271,241M
Income before tax	120,524M	189,466M	263,013M	281,769M	218,113M
Net income	90,874M	135,856M	193,687M	218,701M	164,679M
EBITDA	249,107M	281,757M	338,826M	340,210M	336,104M
Diluted EPS	40.39	61.40	89.62	103.55	81.02
Dividends Per Share	27	30	32	34	36
Total Assets	1,653.10B	1,793.57B	1,799.33B	1,814.07B	1,858.20B
Total liabilities	384,632M	475,662M	540,129M	540,614M	583,608M
Total equity	1,268.47B	1,317.91B	1,259.20B	1,271.81B	1,268.28B
Operating cash flow	217,579M	189,977M	316,534M	237,230M	314,463M

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018
Revenue	11,379.57M	11,353.53M	11,431.18M	12,112.80M	11,732.27M
Gross Profit	7,719.57M	7,968.55M	8,283.53M	8,822.11M	8,754.00M
Operating income	1,844.86M	1,968.77M	2,245.40M	2,552.63M	2,447.30M
Income before tax	1,203.17M	1,724.66M	2,190.23M	2,602.04M	1,967.95M
Net income	907.18M	1,236.66M	1,612.92M	2,019.63M	1,485.83M
EBITDA	2,486.80M	2,564.77M	2,821.56M	3,141.72M	3,032.54M
Diluted EPS	0.40	0.55	0.74	0.95	0.73
Dividends Per Share	0.26	0.27	0.26	0.31	0.32
Total Assets	16,051.92M	14,955.82M	16,009.05M	16,279.92M	17,472.54M
Total liabilities	3,734.83M	3,966.32M	4,805.63M	4,851.60M	5,487.61M
Total equity	12,317.09M	10,989.50M	11,203.42M	11,413.53M	11,925.61M
Operating cash flow	2,172.06M	1,729.31M	2,635.93M	2,190.74M	2,837.28M

Valuation Measures

Mar 2018
PER	19.89
ROA	8.96%
ROE	12.96%
Operating margin	20.85%
Profit margin	12.66%

Key executives

President, CEO & Representative Director: Kenji Yasukawa
Chief Financial Officer: Chikashi Takeda
General Manager-Pharmaceutical Technology: Mitsunori Matsuda
Executive Officer & Head-Compliance: Fumiaki Sakurai
Senior Vice President-Corporate Communications: Stig Ogata

Shareholders

Nomura Asset Management Co., Ltd. (4.4%)
Asset Management One Co., Ltd. (4.2%)
BlackRock Fund Advisors (4.0%)
Nippon Life Insurance Co. (3.2%)
Nikko Asset Management Co., Ltd. (2.8%)
BlackRock Japan Co., Ltd. (2.6%)
The Vanguard Group, Inc. (2.4%)
Daiwa Asset Management Co. Ltd. (2.0%)
Wellington Management Co. LLP (1.6%)
Norges Bank Investment Management (1.4%)

Contact Details

Website:http://www.astellas.com
Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
Phone: +81.3.3244.3000

Related Companies

Astellas Pharma, Inc. /Agensys Research Facilities/
Astellas Pharma, Inc. /16 Long Listed Products/
Astellas Farma Colombia
Astellas Pharma Director Incentive Plan
Astellas Pharma, Inc. /Kiyosu Plant/
PT Astellas Pharma Indonesia
Astellas Pharma ZAO
Astellas Pharma ilac Ticaret ve Sanayi AS
Astellas Pharma Hong Kong Co. Ltd.
Astellas Pharma India Pvt Ltd.
Astellas Pharma Thailand Co. Ltd.
Astellas Pharma Australia Pty Ltd.
Astellas Pharma Singapore Pte Ltd.
Astellas Pharma Tech Co., Ltd.
Mitobridge, Inc.
Astellas Pharma China, Inc.
Perseid Therapeutics LLC
GPDC Partnership
Astellas Pharma Philippines, Inc.
Astellas Pharma Co. Ltd.
Astellas Pharma Canada, Inc.
Fujisawa Taiwan Co. Ltd.
Astellas Pharma SARL
Astellas Pharma Netherlands
Yamanouchi Health & Beauty Co. Ltd.
Yabrofarma Lda.
Fujisawa Ireland Ltd.
Astellas Pharma Korea, Inc.
Yamanouchi USA, Inc.
Astellas Pharma SP zoo

Competitors

Antibiotice SA
YungShin Global Holding Corp.
Coland Holdings Ltd.
Regeneron Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
Ipsen SA
Galapagos NV
Pieris Pharmaceuticals, Inc.
Catabasis Pharmaceuticals Inc
BioLineRX Ltd.
Antares Pharma, Inc.
ArQule, Inc.
Reata Pharmaceuticals, Inc. Class A
Compugen Ltd.
Cidara Therapeutics, Inc.
ESSA Pharma Inc
Sophiris Bio Inc.
Veloxis Pharmaceuticals A/S
Matinas BioPharma Holdings, Inc.
GTx, Inc.
Xenon Pharmaceuticals Inc.
Melinta Therapeutics, Inc.
Kura Oncology, Inc.
Cellular Biomedicine Group, Inc.
GlobeImmune, Inc.
ImmunoGen, Inc.
Sonoma Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Novus Therapeutics, Inc.
SCYNEXIS, Inc.

Last Updated on 20 Jul, 2018

Welcome to our new website

Astellas Pharma, Inc.

Japan

Ticker

Prev. close

Market cap (JPY)

Market cap (USD)

Shares